GOL Completes First International Flight with Alternative Biofuel
Brazilian airline GOL completed its first international commercial flight this week using farnesane, a recently approved renewable jet fuel that is made from sugarcane and produced by industrial bioscience company Amyris.
The flight departed from Orlando, Florida on July 30, 2014 at 5:15 p.m. ET and traveled to Sao Paulo, Brazil.
GOL has committed to fly its Boeing 737 fleet with up to a 10 percent blend of the renewable farnesane fuel starting with the July 30 flight.
Farnesane can reduce greenhouse gas emissions by up to 80 percent compared to petroleum fuels. When blended with Jet A/A1 fuel at 10 percent, farnesane can also reduce particulate matter emissions, decreasing pollution near airports and major metropolitan areas.
The renewable jet fuel is drop-in and can be blended directly with petroleum jet fuel without any changes to airplanes, engines or fueling infrastructure. Amyris will now begin to quantitatively measure the positive impact to GHG emissions and air quality with every flight using the renewable jet fuel.
Earlier this year, ASTM revised the ASTM for jet fuel standard, paving the way for airlines to use Synthesized Iso-Paraffin farnesane as a jet fuel component in commercial airlines globally.
Amyris is one of several alternative fuel developers that have been racing to bring their product to market before government support becomes more unpredictable and private investment dollars dry up, according to a recent report.
Stay Up-to-Date On Environmental Management, Energy & Sustainability News with EL's Free Daily Newsletter
Energy Manager News
- Bridgewater, MA, Gets $231,000 Efficiency Grant
- Biomass Group Studies Role in Clean Power Plan
- Rockleigh Borough Installing LEDs, Low Energy AC
- PHG to Build Big Gasification Plant for Sevier Solid Waste
- Energy Profile of Commercial Buildings Changing
- Smart Meter Market Surging
- Modular Data Centers Cut Construction Costs
- Failure to Build Energy Infrastructure Could Cost New England $5.4B